Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1689302
PUBLISHER: GlobalData | PRODUCT CODE: 1689302
Prostate Cancer: Epidemiology Forecast to 2033
PUBLISHED:
PAGES: 51 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.4 million men were diagnosed with prostate cancer in 2020 (Wang et al., 2022). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (Siegel et al., 2020). Approximately one in seven American men are diagnosed with prostate cancer in their lifetime. However, most are diagnosed after age 65 years, and patients often live long enough that they die of other causes (National Cancer Institute, 2024). Homologous recombination deficiency (HRD) mutations, which affect the DNA repair pathway, increase a man's risk of contracting prostate cancer (Heeke et al., 2018a, 2018b). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2024).
Scope
- This report provides an overview of the risk factors, comorbidities, and global and historical trends for prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at ages 30 years) and stage at diagnosis (stage I, IIA, IIB, III, IV-M0, and IV-M1). Additionally, this report forecasts five-year diagnosed prevalent cases of prostate cancer segmented by stage (stage I-II, III, and IV-M0 and IV-M1), progressed cases (local and regional to stage IV-M0 and IV-M1), Gleason scores (2-10), metastatic and non-metastatic CRPC cases, and DNA repair mutations in metastatic CRPC (mCRPC) cases. Finally, the epidemiology model corresponding to this report presents prostate cancer diagnosed incident cases by Gleason scores (2-10).
Reasons to Buy
The Prostate Cancer Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global prostate cancer markets.
- Quantify patient populations in the global prostate cancer markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the groups that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
- Understand magnitude of the prostate cancer population by age, staging, progression and biomarkers.
Product Code: GDHCER334-25
Table of Contents
Table of Contents
List of Tables
List of Figures
- About GlobalData
1 Prostate cancer: Executive Summary
- 1.1 Catalyst
- 1.2 Related reports
- 1.3 Upcoming reports
2 Epidemiology
- 2.1 Disease background
- 2.2 Risk factors and comorbidities.
- 2.3 Global and historical trends
- 2.4 8MM forecast methodology
- 2.4.1 Sources
- 2.4.2 Forecast assumptions and methods
- 2.4.3 Forecast assumptions and methods: diagnosed incident cases of prostate cancer
- 2.4.4 Forecast assumptions and methods: diagnosed incident cases of prostate cancer by stage at diagnosis
- 2.4.5 Forecast assumptions and methods: five-year diagnosed prevalent cases of prostate cancer 26
- 2.4.6 Forecast assumptions and methods: five-year diagnosed prevalent cases of prostate cancer by Gleason scores
- 2.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of prostate cancer by stages
- 2.4.8 Forecast assumptions and methods: five-year diagnosed prevalent cases of prostate cancer that progress from local and regional to advanced stages
- 2.4.9 Forecast assumption and methods: five-year diagnosed prevalent cases (metastatic and non-metastatic) that progress from hormone-sensitive disease to CRPC by status
- 2.4.10 Forecast assumption and methods: five-year diagnosed prevalent cases of prostate cancer by mutations and biomarkers
- 2.5 Epidemiological forecast for prostate cancer (2023-33)
- 2.5.1 Diagnosed incident cases of prostate cancer
- 2.5.2 Age-specific diagnosed incident cases of prostate cancer
- 2.5.3 Diagnosed incident cases of prostate cancer by stages
- 2.5.4 Five-year diagnosed prevalent cases of prostate cancer
- 2.5.5 Five-year diagnosed prevalent cases of prostate cancer by Gleason scores
- 2.5.6 Five-year diagnosed prevalent cases by stage
- 2.5.7 Five-year diagnosed prevalent cases of prostate cancer with progression to advanced stages
- 2.5.8 Five-year diagnosed prevalent cases of prostate cancer that progress from hormone-sensitive disease to CRPC by status
- 2.5.9 Five-year diagnosed prevalent cases of mCRPC with DNA repair mutations
- 2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 COVID-19 impact
- 2.6.3 Limitations of the analysis
- 2.6.4 Strengths of the analysis
3 Appendix
- 3.1 Bibliography
- 3.2 Primary market research - Prescriber survey
- 3.3 About the Authors
- 3.3.1 Epidemiologist
- 3.3.2 Reviewers
- 3.3.3 Vice President of Disease Intelligence and Epidemiology
- 3.3.4 Global Head of Pharma Research, Analysis and Competitive Intelligence
- Contact Us
Product Code: GDHCER334-25
List of Table
List of Tables
- Table 1: Summary of newly added data types
- Table 2: Summary of updated data types
- Table 3: Risk factors and comorbidities for prostate cancer
- Table 4: High-prescribing physicians surveyed, by country
List of Figure
List of Figures
- Figure 1: 8MM, diagnosed incident cases of prostate cancer, men, N, ages >=30 years, 2023 and 2033
- Figure 2: 8MM, five-year diagnosed prevalent cases of prostate cancer, men, N, ages >=30 years, 2023 and 2033
- Figure 3: 8MM, diagnosed incidence of prostate cancer, men, N, ages >=30 years, 2013-33
- Figure 4: 8MM, five-year diagnosed prevalence of prostate cancer, men, N, ages >=30 years, 2017-33
- Figure 5: 8MM, sources used and not used to forecast the diagnosed incident cases of prostate cancer
- Figure 6: 8MM, sources used to forecast the diagnosed incident cases of prostate cancer by staging
- Figure 7: 8MM, sources used to forecast the five-year diagnosed prevalent cases of prostate cancer
- Figure 8: 8MM, sources used to forecast the five-year diagnosed prevalent cases of prostate cancer by Gleason scores
- Figure 9: 8MM, sources used to forecast the five-year diagnosed prevalent cases of prostate cancer by staging
- Figure 10: 8MM, sources used to forecast the five-year diagnosed prevalent cases of CRPC
- Figure 11: 8MM, sources used to forecast the five-year diagnosed prevalent cases prevalent cases of prostate cancer by progression from hormone-sensitive disease to CRPC by status
- Figure 12: 8MM, sources used to forecast the five-year diagnosed prevalent cases of mCRPC by DNA repair mutations
- Figure 13: 8MM, diagnosed incident cases of prostate cancer, men, N, ages >=30 years, 2023
- Figure 14: 8MM, age-specific diagnosed incident cases of prostate cancer, men, N, ages >=30 years, 2023
- Figure 15: 8MM, diagnosed incident cases of prostate cancer by stage at diagnosis, men, N, ages >=30 years, 2023
- Figure 16: 8MM, five-year diagnosed prevalent cases of prostate cancer, men, N, ages >=30 years, 2023
- Figure 17: 8MM, five-year diagnosed prevalent cases of prostate cancer by Gleason score, men, N, ages >=30 years, 2023
- Figure 18: 8MM, five-year diagnosed prevalent cases by stages, men, N, ages >=30 years, 2023
- Figure 19: 8MM, five-year diagnosed prevalent cases prostate cancer with progression to advanced stage, men, N, ages >=30 years, 2023
- Figure 20: 8MM, five-year diagnosed prevalent cases of prostate cancer that progress from hormone-sensitive disease to CRPC by status, men, N, ages >=30 years, 2023
- Figure 21: 8MM, diagnosed prevalent cases of mCRPC with DNA repair mutations, men, N, ages >=30 years, 2023
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.